NCT07168772View on ClinicalTrials.gov

The Effect of a Probiotic Administration as an add-on Treatment in Multiple Sclerosis

NARecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Multiple Sclerosis
Interventions
DIETARY_SUPPLEMENT

Lactibane Iki

Patients will receive a probiotic sachet twice a day for six months. The probiotic, Lactibiane iki (Pileje; Paris, France), is composed of Bifidobacterium lactis LA 304, Lactobacillus acidophilus LA 201, and Lactobacillus salivarius LA 302 and contains 4x10E10 CFU/sachet.

OTHER

Placebo

Patients will receive a placebo (starch) sachet twice a day for six months.

Trial Locations (1)

08035

RECRUITING

Centre d'Esclerosi Mútiple de Catalunya (Cemcat), Barcelona

All Listed Sponsors
lead

Hospital Universitari Vall d'Hebron Research Institute

OTHER

NCT07168772 - The Effect of a Probiotic Administration as an add-on Treatment in Multiple Sclerosis | Biotech Hunter | Biotech Hunter